SPRING HOUSE, Pa., Dec. 4, 2019 /PRNewswire/ -- Cognizance Biomarkers, LLC, a wholly-owned subsidiary of Evogen, Inc., a leader in proteomic and genomic-based testing for improved diagnosis and ...
Researchers have developed a new test method to measure treatment success in epilepsy patients. They hope that this will enable doctors to react more precisely when treating the disease. Breath ...
Researchers from Lund University in Sweden have discovered higher levels of immune proteins in the blood before and after an epileptic seizure. The possible biomarkers can be identified using a simple ...
Epilepsy is the world's most common chronic neurological condition, affecting about 1 in every 100 people. Those who have it ...
Epilepsy affects some 50 million people worldwide and pharmaceutical treatment of the disease is a tightrope walk, as the dose must be tailored precisely to the individual patient: "Slightly too ...
WOBURN, Mass.--(BUSINESS WIRE)--Courtagen Life Sciences, Inc., an innovative molecular information company, announced today the release of a Next Generation Sequencing test focused on detection of ...
Royal Oak — Four-year-old Joey Owen showed up at Beaumont Hospital ready to "Hulk smash" his most recent electroencephalogram, a brain test needed to monitor his epilepsy. "He has screamed and cried ...
FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx announced today that it will be presenting its Genomic Unity ® Epilepsy Analysis testing program at the American Epilepsy Society (AES) annual meeting ...
The University of Utah College of Pharmacy's Anticonvulsant Drug Development (ADD) Program has been awarded a five-year $19.5 million contract renewal with the National Institutes of Health (NIH) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback